News Release

After 7 months of research, Cullgen has filed 2 PCT patents for new anti-cancer drug candidates. Vice President of Chemistry, Dr. Michael Plewe, will present the updated research at the Targeted Protein Degradation Summit in Boston, USA, on October 25, 2018.